Validated biomarker assays confirm that <scp>ARID1A</scp> loss is confounded with <scp>MMR</scp> deficiency, <scp> CD8 <sup>+</sup> TIL </scp> infiltration, and provides no independent prognostic value in endometriosis‐associated ovarian carcinomas
Karolin Heinze(University of British Columbia), Yurii B. Shvetsov(University of Hawaiʻi at Mānoa), Minouk J. Schoemaker(Institute of Cancer Research), Derek S. Chiu(University of British Columbia), F. Kommoss(Heidelberg University), Linda S. Cook, Annette Staebler, Esther Elishaev(University of Pittsburgh), Penny Coulson(Institute of Cancer Research), Kylie L. Gorringe(The University of Melbourne), Michael E. Carney(The University of Texas MD Anderson Cancer Center), Florian Heitz(Kliniken Essen-Mitte), Angela Laslavic(University of Pittsburgh), Jan Lubiński(Tumour Institute of Tuscany), Anna DeFazio(The University of Sydney), Michael E. Jones(Institute of Cancer Research), Anthony J. Swerdlow(Institute of Cancer Research), Helena Gronwald(Pomeranian Medical University), Sabine Heublein(Heidelberg University), Ian Campbell(The University of Sydney), Samuel Leung(BC Cancer Agency), Simon A. Gayther(The University of Texas Health Science Center at Houston), Andreas du Bois(Kliniken Essen-Mitte), Catherine J. Kennedy(The University of Sydney), Marcin Lener(International Hereditary Cancer Center), Kirsten B. Moysich(American Cancer Society), Renée T. Fortner(Norwegian Institute of Public Health), Jessica Boros(The University of Sydney), Evan S. Cairns(University of British Columbia), Marcel Grube(University of British Columbia), Bernhard Kraemer(University Children's Hospital Tübingen), Mona El‐Bahrawy(Al-Azhar University), Paul R. Harnett(The University of Sydney), Francesmary Modugno(University of Pittsburgh), Alison H. Brand(The University of Sydney), Philipp Harter(Kliniken Essen-Mitte), Tayyebeh M. Nazeran(BC Cancer Agency), Naveena Singh(University of British Columbia), Cezary Cybulski(International Hereditary Cancer Center), Raghwa Sharma(Royal Prince Alfred Hospital), Jacek Gronwald(International Hereditary Cancer Center), Sandra Lee(University of Calgary), Pauline Krämer(University of British Columbia), Aleksandra Tołoczko‐Grabarek(Pomeranian Medical University), Alex Olawaiye(University of Pittsburgh), Hans‐Walter Vollert(Medizin Campus Bodensee), Friedrich Kommoss(Heidelberg University), Hans‐Peter Sinn(Heidelberg University), Eun Young Kang(University of Calgary), Nicola S. Meagher(The University of Sydney)
Cited by 42
Related Papers
Average Risks of Breast and Ovarian Cancer Associated with BRCA1 or BRCA2 Mutations Detected in Case Series Unselected for Family History: A Combined Analysis of 22 Studies
|The American Journal of Human Genetics|2003|3.7k
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial
|The Lancet Oncology|2017|1.9k
Whole–genome characterization of chemoresistant ovarian cancer
|Nature|2015|1.7k
Novel Molecular Subtypes of Serous and Endometrioid Ovarian Cancer Linked to Clinical Outcome
|Clinical Cancer Research|2008|1.5k